BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9625433)

  • 41. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
    Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
    J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
    [TBL] [Abstract][Full Text] [Related]  

  • 42. All-trans retinoic acid and interferon-alpha for treatment of human renal cell carcinoma multicellular tumor spheroids.
    Rohde D; Brkovic D; Hönig d'Orville I
    Urol Int; 2004; 73(1):47-53. PubMed ID: 15263793
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synergistic effect of retinoids and interferon alpha on tumor-induced angiogenesis: anti-angiogenic effect on HPV-harboring tumor-cell lines.
    Majewski S; Szmurlo A; Marczak M; Jablonska S; Bollag W
    Int J Cancer; 1994 Apr; 57(1):81-5. PubMed ID: 7512078
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Modulation of cisplatin sensitivity and accumulation by interferon alpha-2A in human squamous carcinoma cell lines.
    Gupta V; Jani JP; Emerson EO; Xu BH; Scalamogna D; Xia H; Katoh A; Zaren HA; Singh SV
    Int J Cancer; 1995 Nov; 63(3):419-22. PubMed ID: 7591242
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells.
    Tyagi AK; Agarwal C; Chan DC; Agarwal R
    Oncol Rep; 2004 Feb; 11(2):493-9. PubMed ID: 14719089
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interaction of retinoic acid and interferon in renal cancer cell lines.
    Nanus DM; Geng Y; Shen R; Lai HK; Pfeffer SR; Pfeffer LM
    J Interferon Cytokine Res; 2000 Sep; 20(9):787-94. PubMed ID: 11032398
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Activity- and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in cisplatin-sensitive and -refractory human ovarian carcinoma cell lines.
    Klaassen U; Harstrick A; Schleucher N; Vanhoefer U; Schröder J; Wilke H; Seeber S
    Br J Cancer; 1996 Jul; 74(2):224-8. PubMed ID: 8688325
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.
    Sharp SY; Mistry P; Valenti MR; Bryant AP; Kelland LR
    Cancer Chemother Pharmacol; 1994; 35(2):137-43. PubMed ID: 7987990
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Determination of in vitro drug sensitivity to a panel of cystostatic drugs and interferon alpha-2b in patients with renal cell carcinoma.
    Küpeli S; Beksac M; Küpeli B; Baltaci S; Süzer O
    Int Urol Nephrol; 1997; 29(4):421-6. PubMed ID: 9405998
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Potentiation of cisplatin cytotoxicity in human ovarian carcinoma cell lines by trifluoperazine, a calmodulin inhibitor.
    Perez RP; Handel LM; Hamilton TC
    Gynecol Oncol; 1992 Jul; 46(1):82-7. PubMed ID: 1634144
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combination of all-trans retinoic acid and interferon-gamma suppressed PI3K/Akt survival pathway in glioblastoma T98G cells whereas NF-kappaB survival signaling in glioblastoma U87MG cells for induction of apoptosis.
    Zhang R; Banik NL; Ray SK
    Neurochem Res; 2007 Dec; 32(12):2194-202. PubMed ID: 17616812
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interferon-alpha and interferon-gamma combined with chemotherapy: in vitro sensitivity studies in non-small cell lung cancer cell lines.
    Hand A; Pelin K; Halme M; Ekman A; Mattson M; Vallas M; Mattson K; Linnainmaa K; Husgafvel-Pursiainen K
    Anticancer Drugs; 1993 Jun; 4(3):365-8. PubMed ID: 8395259
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modulation of p53 expression by human recombinant interferon-alpha2a correlates with abrogation of cisplatin resistance in a human melanoma cell line.
    Davol PA; Goulette FA; Frackelton AR; Darnowski JW
    Cancer Res; 1996 Jun; 56(11):2522-6. PubMed ID: 8653690
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Does interferon-alpha enhance the effect of tamoxifen-medroxyprogesterone acetate and hydroxyflutamide on in vitro tumor cells?].
    Werner A; Aichberger A; Krebs D
    Zentralbl Gynakol; 1996; 118(11):616-21. PubMed ID: 9082695
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects.
    Wadler S; Wersto R; Weinberg V; Thompson D; Schwartz EL
    Cancer Res; 1990 Sep; 50(18):5735-9. PubMed ID: 1697499
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of DNA repair and sensitization of cisplatin in human ovarian carcinoma cells by interleukin-1 alpha.
    Benchekroun MN; Parker R; Reed E; Sinha BK
    Biochem Biophys Res Commun; 1993 Aug; 195(1):294-300. PubMed ID: 8363610
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.
    Chou TC; Motzer RJ; Tong Y; Bosl GJ
    J Natl Cancer Inst; 1994 Oct; 86(20):1517-24. PubMed ID: 7932806
    [TBL] [Abstract][Full Text] [Related]  

  • 58. All-trans retinoic acid and interferon-alpha-2a in patients with metastatic or recurrent carcinoma of the uterine cervix: clinical and pharmacokinetic studies. New York Gynecologic Oncology Group.
    Wadler S; Schwartz EL; Haynes H; Rameau R; Quish A; Mandeli J; Gallagher R; Hallam S; Fields A; Goldberg G; McGill F; Jennings S; Wallach RC; Runowicz CD
    Cancer; 1997 Apr; 79(8):1574-80. PubMed ID: 9118041
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Effects of interferon-gamma combined with all-trans retinoic acid on proliferation and differentiation of leukemia cell lines NB4 and MR2].
    He PC; Zhang M; Wu D; Xu H; Cai RB; Liu YL
    Ai Zheng; 2006 Dec; 25(12):1477-82. PubMed ID: 17166370
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
    Kawano M; Mabuchi S; Kishimoto T; Hisamatsu T; Matsumoto Y; Sasano T; Takahashi R; Sawada K; Takahashi K; Takahashi T; Hamasaki T; Kimura T
    Int J Gynecol Cancer; 2014 Jun; 24(5):829-37. PubMed ID: 24844217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.